Germfree

How can we accelerate patient access to life-saving therapies? In her contribution to Cell & Gene Therapy Review’s 2025 Predictions Series, Carol Houts addresses the biggest challenge facing the cell and gene therapy (CGT) sector in 2025: enhancing patient access through more efficient and scalable manufacturing solutions. With traditional centralized models causing delays, the industry is now embracing decentralized and point-of-care manufacturing to bring treatments directly to patients, faster and more efficiently. Discover more about the future of CGT and its potential for global accessibility: https://hubs.ly/Q03fP0JW0 #CellAndGeneTherapy #Germfree #CGT #PointOfCare

Is it time to rethink how we manufacture cell therapies? 🤔 For patients in need of life-saving treatments, time is everything. Yet, manufacturing bottlenecks continue to delay treatment, leaving up to 20% of eligible patients without access in time. At #ATW25, Germfree’s Sean Bartholomew, Edwin Stone of Cellular Origins, and Shannon Eaker of xcellbio, joined our IBTV Spotlight to discuss how the industry can break these barriers. Edwin shares how optimized manufacturing (choosing the right approach for each therapy, not just centralized or decentralized models) can break barriers and improve speed, viability, and access. 🙌 📽️ Watch the full spotlight for additional insights on how the industry can remove roadblocks and get life-saving therapies to patients faster. ➡️ https://hubs.ly/Q03f4yYL0 #AdvancedTherapiesWeek #IBTVSpotlight #CellTherapy #PatientAccess

Last chance to register! The On Demand Pharmaceuticals Inc and Germfree webinar, "Embracing Today, Shaping Tomorrow: Driving Innovation in Decentralized Manufacturing", is happening TODAY at 11 AM ET! 👏 Don’t miss this opportunity to learn how decentralized manufacturing is tackling drug shortages and bringing life-saving medications closer to patients. With medication shortages at an all-time high, hospitals and healthcare providers need better solutions to ensure a stable, local drug supply. Join Sean Bartholomew (Germfree) and John Lewin (On Demand Pharmaceuticals) as they discuss how on-site, on-demand drug production is transforming healthcare by reducing supply chain risks and ensuring critical medications are available when and where they’re needed. ⏳ Time is running out. Register now before it’s too late! ➡️ https://hubs.ly/Q03dmbN90 #Webinar #DrugShortage #Healthcare #DecentralizedManufacturing #Innovation

At Germfree, we’re all about making the cleanroom design and construction process smoother for you from start to finish. Our detailed approach—starting with conceptual design and ending with post-installation support—ensures your cleanroom meets every requirement with precision and efficiency. With each phase, we focus on tailored solutions, expert craftsmanship, and regulatory compliance. 🙌 From initial design to global support, our team is dedicated to delivering top-notch facilities that work for you, no matter where you are. 🌍 Ready to get started? Let’s connect today! ➡️ https://hubs.ly/Q03dt2r50 #OurProcess #Cleanroom #CleanroomDesign #RegulatoryCompliance #EndtoEndSolutions

Clinical readiness is essential for the successful adoption of cell and gene therapies (CGTs)—but where do clinical centers even begin? 🤔 In this IBTV Spotlight from Advanced Therapies Week 2025, Germfree's Carol Houts explains why organizations like the Foundation for the Accreditation of Cellular Therapy (FACT) are critical for clinical centers to understand accreditation, business cases, and patient care. This insightful discussion also features Josh Ludwig (ScaleReady), Heather Purvis (Title21 Health Solutions), and Priya Baraniak, Ph.D. (Pluristyx, Inc.), all sharing their expertise on overcoming the challenges to accelerate patient access. 👀 Watch the full spotlight now to gain deeper insights on how to overcome challenges and expand the adoption of CGTs. ➡️ https://hubs.ly/Q03dhzLm0 #ATW25 #ClinicalReadiness #IBTVSpotlight #CellTherapy #GeneTherapy #PatientAccess

Only one week left until our highly anticipated webinar with On Demand Pharmaceuticals and Pharmaceutical Online! 👏 Join us next Thursday, March 27, 2025 at 11:00 AM ET, for an in-depth conversation featuring Sean Bartholomew from Germfree and John Lewin from On Demand Pharmaceuticals. They will explore the urgent need for decentralized manufacturing in healthcare, especially as drug shortages continue to affect hospitals across the U.S. and millions lack access to critical medications worldwide. The discussion will highlight how on-site, on-demand production is reshaping efficiency and patient care by solving these challenges and enhancing global drug access. 🌍💊 You’ll also get an exclusive look at the exciting collaboration between Germfree and On Demand Pharmaceuticals, driving innovation in this space. 👀 Don’t miss this opportunity to learn from industry leaders—register today to secure your spot! ➡️ https://hubs.ly/Q03chyxN0 #Webinar #DecentralizedManufacturing #DrugShortages #PatientAccess #MobilePharmacy #PharmacyOnDemand

Protecting Hawaiian Agriculture with Cutting-Edge Pathogen Research 🌱 Plant pathogens threaten local crops, food security, and Hawaii’s agricultural economy. To combat this, Germfree designed and delivered a Containerized BSL-2 Laboratory, providing a secure, USDA-compliant space for pathogen detection, research, and disease management. This mobile lab brings critical research capabilities directly to the source—helping protect crops, support farmers, and strengthen food security. 💪 Read the full case study to learn more! ➡️ https://hubs.ly/Q03chPJn0 #CaseStudy #Biocontainment #BSL2 #MobileLaboratory

"I would have done CAR-T TEN TIMES over to any single regimen of chemotherapy 😌," shared Brad Watts during our symposium at #ATW25. Cell and gene therapies like CAR-T Cell Therapy are revolutionizing cancer care and other treatments, offering new hope where traditional therapies have failed. But challenges around scalability, cost, and access continue to prevent these life-changing therapies from reaching more patients. During the symposium, moderated by Germfree’s Carol Houts, experts like Alexander Seyf, Phyllis Warkentin, and more, discussed how decentralized manufacturing, digital innovations, and regulatory shifts are crucial in expanding the reach of all cell and gene therapies. How can we ensure innovative treatments, like CAR-T Cell Therapy, reach more patients? By embracing technology, education, and collaboration across the industry. 🙌 Read more about the key insights and actionable strategies shared during this impactful symposium. ➡️ https://hubs.ly/Q03c41x_0 #AdvancedTherapiesWeek #CGT #CART #CellTherapy #GeneTherapy #PatientAccess

A must-watch discussion on the intersection of centralized and decentralized manufacturing in advanced therapies! 👀💡 Germfree’s CCO Carol Houts joined an incredible all-women panel at #ATW2025 to explore how centralized and decentralized manufacturing models complement each other, enhance efficiency, and improve patient access. Catch the highlights from Phacilitate's Advanced Therapies Week and celebrate the women making an impact! 👏 Watch the full panel here: https://lnkd.in/eMjkveWp #AdvancedTherapies #DecentralizedManufacturing #WomenInSTEM #InternationalWomensDay

Great things happen when women lead, innovate, and create. At Germfree, we are proud to have a team of extraordinary women who bring their expertise, strength, and vision to every aspect of our work. From the manufacturing floor to the frontlines of project management, sales, engineering, and beyond—you help shape our success and drive progress every day. Today, we honor and thank you. 💜 Happy International Women’s Day! 🎉 #IWD #WomenAtGermfree #BreakingBarriers #WomenInManufacturing